KERX : Summary for Keryx Biopharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Keryx Biopharmaceuticals, Inc. (KERX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.67+0.15 (+2.72%)
At close: 4:00 PM EST
People also watch:
AEZSCLDXARNAACADOREX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.52
Open5.56
Bid4.00 x 200
Ask5.79 x 2000
Day's Range5.50 - 5.78
52 Week Range2.80 - 7.80
Volume1,047,051
Avg. Volume1,580,674
Market Cap600.79M
Beta3.13
PE Ratio (TTM)-3.63
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Biotech Investing Tips That Could Earn You Thousands
    Motley Fool6 days ago

    3 Biotech Investing Tips That Could Earn You Thousands

    Successful biotech investing oftentimes comes down to making fewer mistakes. Here are several pitfalls to avoid.

  • Capital Cube11 days ago

    ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Keryx Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to KERX-US. Comparing the performance and risk of Keryx Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
    Capital Cube13 days ago

    Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016

    Categories: Yahoo Finance Get free summary analysis Keryx Biopharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Keryx Biopharmaceuticals, Inc. – Sophiris Bio Inc., Ardelyx, Inc., AMAG Pharmaceuticals, Inc., Impax Laboratories, Inc., VIVUS, Inc., Apricus Biosciences, Inc., Momenta Pharmaceuticals, Inc. and Aeterna Zentaris Inc. (SPHS-US, ... Read more (Read more...)